Stromal cell-free conditions favorable for human B lymphopoiesis in culture

Michiko Ichii, Kenji Oritani, Takaumi Yokota, Daniel C. Schultz, Jennifer L. Holter, Yuzuru Kanakura, Paul W. Kincade

1. Introduction

B lineage lymphocytes are produced throughout life from hematopoietic stem cells (HSC) within bone marrow (BM) (Nunez et al., 1996; Rossi et al., 2003; Stephan et al., 1998). While steps in the process have been extensively investigated in mice, progress in understanding human B lymphopoiesis has been hampered by lack of efficient ways to study progenitors in culture (Bertrand et al., 2000; LeBien, 2000). This is partially due to species differences and a growth factor that selectively drives formation of human B cells has not been identified (Pribyl and LeBien, 1996). Some success has been obtained by placing human stem and progenitor cells on monolayers of murine stromal cells (Kurosaka et al., 1999; Nishihara et al., 1998; Ohkawara et al., 1998; Rawlings et al., 1995), and we recently found that human mesenchymal stem cells (hMSC) were even more effective (Ichii et al., 2008). For example, umbilical cord blood (CB) CD34+ cells generated more CD33+ CD13+ myeloid cells and CD10+ CD19+ B lineage lymphocytes in hMSC co-cultures than when the murine MS5 stromal cell line was used. In addition to their support of hematopoiesis (Koç et al., 2000; Muguruma et al., 2006; Zhang et al., 2004), multipotential hMSC are capable of chondrocyte, osteoblast or adipocyte differentiation (Abdallah and Kassem, 2008; Chamberlain et al., 2007; Pittenger et al., 1999). Diffusible factors or membrane ligands on the adherent cells provide signals required for survival, proliferation and differentiation in the B lineage, but the nature of those molecules is poorly understood. Addition of recombinant growth and differentiation factors can be helpful, but optimal conditions have not been found.
A robust, stromal cell-free culture procedure that is based on human factors would have many advantages over existing methods. For example, drugs or biologicals could be screened for direct effects on hematopoietic cells, identifying molecules with therapeutic potential. We have now systematically manipulated culture conditions, finding that hMSC produce soluble, heat-labile factors that support human B lymphopoiesis. The same is true for undefined substances in selected lots of fetal calf serum (FCS), and the active principal was not IL-7, thymic stromal lymphopoietin (TSLP), CXCL12 or hemokinin-1. High cell densities and addition of recombinant granulocyte colony stimulating factor (G-CSF), Stem cell factor (SCF) and flt-3 ligand (FL) were all critical for efficient B lymphopoiesis. While lymphocyte production from adult BM progenitors in culture is much more difficult than umbilical CB cells, both are responsive to G-CSF. This information should now facilitate basic studies of immune system replenishment, improving differentiation schemes useful for classifying malignancies as well as the discovery of cytokines that can counter immunodeficiency resulting from mutations or chemotherapy.

2. Materials and methods

2.1. Origin and isolation of cells

CB cells were collected from healthy, full-term neonates immediately after Caesarean section or normal delivery. BM cells were collected from normal donors. All samples were collected after informed consent, using protocols approved by the Investigational Review Boards at Osaka University and O.M.R.F. Mononuclear cells were separated by Ficoll-Paque PLUS (GE Healthcare Bio-Science AB, Uppsala, Sweden) or Lymphocyte Separation Medium (Mediatech, Inc., Manassas, VA) and centrifugation. Purification of CB and BM CD34+ cells was performed using Direct human CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Auburn, CA). Human mesenchymal stem cells were purchased from Lonza (Walkersville, MD), and maintained in Mesenchymal Stem Cell Growth Medium (MSCGM, Lonza). Flow cytometric analysis confirmed that the cultured hMSC expressed CD105, CD166, CD29, and CD44, but not CD14, CD34, or CD45.

2.2. Co-cultures for human B lymphocytes

Co-cultures of CB CD34+ cells on hMSC were performed as previously described (Ichii et al., 2008). hMSC were seeded in 12-well tissue plates 1 or 2 days before setting up the co-cultures. Isolated CD34+ cells (2×10^3 cells/well) were plated on sub-confluent hMSC layers in MSCGM in the presence of 10 ng/ml SCF and 5 ng/ml FL. Recombinant human SCF and FL proteins were purchased from R&D systems (Minneapolis, NY). Half of the culture medium was replaced with fresh medium containing the same cytokines twice a week. In some experiments, direct contact between hMSC and cultured cells was prevented with...
0.45 μm polyethylene terephthalate membranes (FalconTM Cell Culture Inserts; Becton Dickinson Labware, Franklin Lakes, NJ).

2.3. Stromal cell-free cultures for human B lymphocytes

Isolated CD34+ cells were seeded with cytokines as indicated in the figures. The cultures were usually maintained in QBSF®60 (Quality Biological, Inc., Gaithersburg, MD) containing 10% FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin). Recombinant human IL-7 and G-CSF proteins were purchased from R&D Systems. Half of the culture medium was replaced with fresh medium containing the same cytokines once a week. Supernatants of one week hMSC cultures were collected, filtered and added to lymphocyte cultures. This conditioned medium was incubated for one hour at 56 °C to assess lability and also used in experiments with neutralizing antibodies to IL-7, CXCR4 or TSLP (R&D Systems). A hemokinin-1 inhibitor (L732138) was obtained from Sigma-Aldrich (St. Louis, MO).

2.4. Flow cytometry and cell sorting

Flow cytometric analysis was performed with a FACSCalibur or FACS LSRII (BD Biosciences Immunocytometry Systems, San Jose, CA) using standard multicolor immunofluorescent staining protocols. Mouse monoclonal Abs against the following human cell surface molecules were purchased: PE-CD3, PE-CD10, APC-CD10, PE-CD19, PE-CD20, FITC-CD33, PE-CD34, APC-CD34, FITC-CD45, PE-CD56, and PE-glycoporphin A (GPA) from BD Biosciences/BD Pharmingen (Franklin Lakes, NJ); phycoerythrin 5-succinimidylester (PC5)-CD19 from Beckman Coulter (Marseilles, France); and FITC-IgM from Southern Biotechnology Associates (Birmingham, AL).

2.5. Transplantation of cultured cells into immunodeicient mice

Xenotransplantation of cultured cells from CB CD34+ cells were performed using a previously reported method (Hiramatsu et al., 2003). Briefly, 8- to 12-week old NOD/SCID/common γnull (NOG) mice received 240 cGy radiation divided in two fractions. Isolated CB CD34+ cells or cells generated in stromal cell-free cultures were injected via the tail vein. At intervals after transplantation, peripheral blood cells were taken and assessed for human lineage specific marker expression by flow cytometry. The same mice were sacrificed more than 2 months after transplantation, and phenotypes of BM and spleen cells were analyzed using flow cytometry.

2.6. Statistical analyses

Student’s t-test was performed to assess statistical differences. All results are shown as mean values ± SD.
3. Results

3.1. Mesenchymal stem cells produce unknown, heat-labile factors that promote human B lymphopoiesis

Membrane inserts have been extensively used to probe requirements for physical contact in hematopoietic cell cultures (Miller et al., 1998; Nishihara et al., 1998; Verfaillie, 1993). We used this approach to determine that hMSC or conditioned medium from them supported formation of CD10⁺ CD33⁻ lymphoid cells in cultures of CD34⁺ CB (Fig. 1A, B). The yield of lymphocytes was much less than when hematopoietic cells were in direct contact with hMSC, suggesting that the diffusible factors might be short-acting, and they were completely inactivated by heating for 1 h at 56 °C (Fig. 1C).

Stromal cell derived IL-7 is essential for murine adult B lymphopoiesis (Peschon et al., 1994; Von Freeden-Jeffry et al., 1995) and parts of the IL-7 receptor are used to recognize the cytokine TSLP (Levin et al., 1999; Vosshenrich et al., 2003). Chemokines recognized by the CXCR4 receptor and the hemokinin-1 peptide also influence lymphopoiesis in the mouse (Milne et al., 2004; Tokoyoda et al., 2004; Zhang et al., 2000; Zhu et al., 2007). Addition of neutralizing antibody to IL-7 had no effect on human cord blood cell cultures (Fig. 2A). The same was true for antibodies to the CXCR4 receptor or TSLP, or addition of an inhibitor for hemokinin-1 (Fig. 2B, C). The experiments described above were conducted with a batch of FCS that is optimal for growth of hMSC, and screening revealed no correlation with efficiency of lymphopoiesis (Fig. 3A). All subsequent studies were done with a batch that was optimal in

![Flow cytometry results](image.png)

**Fig. 4.** Characteristics of cells generated in stromal cell-free cultures. (A) CB CD34⁺ cells (1 × 10⁴ cells/ml) were cultured for 5 weeks in the presence of hMSC supernatant (10%), SCF, FL and IL-7. The generated cells were stained with FITC-CD33 and APC-CD10 as well as the indicated PE-conjugated Abs. All of the flow cytometry results shown in panel A were gated for CD33⁻ cells. Isotype-matched Abs were used as negative controls. Similar results were obtained in three independent experiments. (B, C) CB CD34⁺ cells (1 × 10⁴ cells/ml) were cultured with hMSC supernatant (10%), SCF, FL and IL-7 for 4 weeks. The cultured cells were collected, and surface expression of CD10, CD19 and CD33 was determined weekly by flow cytometry. Numbers of CD33⁺ myeloid cells (dotted line) and CD10⁺ CD19⁺ lymphoid cells (solid line) were calculated, and similar results were obtained in three independent experiments.
this respect. Medium selection was another important variable, and QBSF®60 was selected for all of our studies (Fig. 3B). We conclude that while direct contact with stromal cells is not essential for human B lymphopoiesis, unknown stromal cell-derived factors do facilitate this process.

3.2. Characteristics of cells generated in cultures with hMSC conditioned medium

We found that cultures initiated with $1 \times 10^4$ highly enriched CB CD34+ cells together with 10% hMSC conditioned medium, SCF, FL, and IL-7 generated approximately $2 \times 10^6$ CD10+ lymphoid cells within 4 weeks. Fig. 4A shows representative flow cytometry results for cultures held one week longer. Approximately 5% of the cultured cells still expressed CD34, but neither GPA+ erythroid cells nor CD3+ T lineage cells were ever detected. Most of the generated CD10+ cells also expressed CD19, while more than half of them were CD20+. CD33+ myeloid cells peaked after 2 weeks of culture and then CD10+ CD19+ B lineage cells appeared (Fig. 4B, C).

We then assessed the differentiation potential of cells expanded in three week cultures by transplanting $1 \times 10^7$ of them into sub-lethally irradiated, immunodeficient NOG mice. Control animals received $5 \times 10^4$ freshly isolated CB CD34+ cells. CD45+ human cells were detected in peripheral blood of all transplanted mice six weeks later and B lineage lymphoid cells predominated (Fig. 5A). The animals were then sacrificed 3 months after transplantation and more detailed flow cytometry was performed with BM and spleen (Fig. 5B). Human CD19+, CD20+ and IgM+ lymphocytes, but not NK or...
T cells were found in both sites. Similar results were obtained when transplanted mice were examined six months after transplantation. Thus, these culture conditions support the generation of human B lymphoid cells and cultured progenitors retain substantial potential for B lymphopoiesis in chimeric mice.

3.3. Lymphopoiesis can be observed in stromal cell-free, hMSC supernatant-free cultures if cell density is high

Some studies have stressed the importance of high cell density for lymphocyte viability in culture (Milne et al., 2004; Zhang et al., 2000), and we found this was also the case for human lymphoid progenitors (Fig. 6A). In fact, significant numbers of lymphocytes were made even in the absence of hMSC or their products when cultures were initiated with greater than $5 \times 10^3$ CB CD34+ cells/ml. These generated cells had similar surface phenotypes to the cultured cells with 10% hMSC conditioned medium shown in Fig. 4A (data not shown). A series of cultures were then set up with a starting density of $1 \times 10^4$ cells/ml and subgroups were then diluted to this same density at intervals of 1, 2 or 3 weeks of culture. Total nucleated cells expanded approximately 500 fold in the control, unmanipulated group and this was the most efficient condition for generating lymphocytes (Fig. 6B). Adjustment of the density at any subsequent time, and especially during the first two weeks, compromised lymphocyte recovery. Note that non-lymphoid cells represented in the total nucleated cell counts expanded well when culture cell numbers were readjusted on weeks two and three. Also, crowding of cells in round bottom rather than flat bottom 96 well trays improved cloning efficiencies for human progenitors (data not shown). Therefore, contact between maturing hematopoietic progenitors favors their survival, proliferation and/or differentiation.

3.4. Addition of recombinant G-CSF promotes lymphopoiesis even with adult marrow progenitors

The developmental age of hematopoietic cell donors has a strong influence over their potential to generate lymphocytes.
in culture (Rossi et al., 2003). That is, conditions that support vigorous lymphopoiesis from CB CD34+ cells yield few lymphocytes with progenitors harvested from adult BM. We observed this phenomenon when cells of the two types were cultured on hMSC or in conditioned medium from hMSC, regardless of the initial cell density (Fig. 7A and data not shown). It was reported that G-CSF facilitated lymphopoiesis in co-cultures with murine stromal cells (Nishihara et al., 1998), and we found the same was true in stromal cell-free cultures (Fig. 7B and C). That is, even CD34+ cells from adult BM generated lymphocytes when this recombinant cytokine was present. Yields of lymphocytes were best when recombinant SCF and G-CSF were added together and refreshed with each weekly medium change. Progenitors from umbilical CB were less fastidious than those from adult marrow (Fig. 7A). However, even CB 34+ cells generated more lymphocytes in culture when G-CSF was present (Fig. 7D).

4. Discussion

It is believed that bone marrow contains specialized niches where B lineage lymphocytes are generated (Tang et al., 1993; Tokoyoda et al., 2004; Zhu et al., 2007). However, the molecules that comprise these lymphopoietic micro-environments are poorly understood. To our knowledge, this represents the first successful generation of human B lineage lymphocytes in stromal cell-free cultures. Important variables include selection of fetal calf serum lots, appropriate medium, high cell density and addition of G-CSF. Cultures initiated with 1 × 10^6 CB CD34+ cells/ml or 5 × 10^4 BM CD34+ cells/ml in QBSF®60 contained with 10% selected FCS, SCF, FL, and G-CSF generated CD10+ CD19+ lymphoid cells within 4 weeks. Although far from being an efficient system, it provides an opportunity to systematically screen candidate substances and learn how diffusible factors regulate replenishment of the humoral immune system.

Assessment of survival and growth of lymphoid leukemia may represent another application of this new technology.

G-CSF was discovered for its support of myelopoiesis, and while it is not made by hMSC under normal steady-state conditions, the factor is produced by osteoblasts (Eaves et al., 1991; Majumdar et al., 2000; Taichman and Emerson, 1994; Zhang et al., 2004). B lineage progenitors were also mobilized in patients whose stem cells were mobilized by injection of this cytokine (Imamura et al., 2005). In addition, the factor augmented human lymphopoiesis when added to co-cultures supported by murine MS5 stromal cells (Nishihara et al., 1998; Ohkawara et al., 1998). The same investigators reported that lymphoid and non-lymphoid cells have G-CSF receptors. We have now found that G-CSF directly stimulates human CD34+ cells and supports their ability to generate B lymphopoiesis. The effect was most pronounced when stem and progenitors from adult BM was used to initiate cultures. It may be that G-CSF is functioning as a multipoietin, improving the retention of CD34+ cells that subsequently generate lymphocytes. However, we have also found that G-CSF augments lymphocyte formation in cultures initiated with Lin− CD34+ CD38+ CD123− CD45RA+ CD10− lymphoid progenitors (M.I. unpublished observations).
Consistent with many previous studies (Pribyl and LeBien, 1996; Puel et al., 1998), we found no influence of IL-7 on B lymphopoiesis in human cultures and active heat-labile substances released by stromal cells remain undefined. TSLP is a cytokine that preferentially expands fetal lymphopoiesis in mice (Levin et al., 1999; Vosshenrich et al., 2003). Consistent with that, addition of the factor augmented lymphocyte formation in cultures initiated with human cord blood, but not adult marrow progenitors in preliminary experiments (data not shown). However, addition of neutralizing TSLP specific antibodies to our cultures did not identify it as an activity in hMSC supernatants.

High cell densities reportedly improve murine pre-B cell survival in part because of their release of hemokinin-1 (Milne et al., 2004; Zhang et al., 2000). Autocrine lymphocyte-derived factors may also be important for human progenitors, but we never observed changes in cultures treated with Hemokinin-1 or an inhibitor specific for it. Chemokines such as CXCL12 may be recognized by CXCR4 on progenitors and deliver pro-adhesive signals important within bone marrow (Tokoyoda et al., 2004; Zhu et al., 2007), but there was no obvious role for this receptor in our stromal cell-free cultures.

It is noteworthy that B lineage lymphocytes always appeared after the expansion of myeloid cells in all culture conditions. When limiting numbers of CD34+ cells were used to initiate cultures, some wells contained myeloid cells but no lymphocytes. Even highly enriched murine stem cell populations are heterogeneous, and it is believed that subsets differ with respect to lymphopoietic potential. The methods we describe here may suggest experimental approaches to such questions with human stem cells.

Fetal and neonatal CD34+ cells differ from their adult counterparts in multiple ways (Ng et al., 2004; Wang et al., 1997; Weelx et al., 1998). For example, cord blood cells slowly reconstitute adult transplant recipients but smaller numbers are effective (Laughlin et al., 2004; Schmitz and Barrett, 2002). A better understanding of these differences may lead to improved and accelerated transplant recovery as well as reduced incidences of disease relapse. Neonatal cells have also been more robust and less fastidious in previous lymphoid culture studies (Ichii et al., 2008; Rossi et al., 2003). As noted above, G-CSF preferentially influences adult progenitors but lymphopoiesis is still less efficient than when cord blood CD34+ cells are used. Again, experimental approaches involving cultures might be used to seek a molecular basis for neonatal/adult differences.

These findings represent an increase in techniques for observing human B lymphopoiesis in culture. While there is considerable room for further improvement, it is already clear that complex questions about species specific and lymphoid leukemia regulators as well as stem and progenitor cell heterogeneity can now be addressed.

Acknowledgments

The authors thank Shelli Wasson for editorial assistance and Beverly Hurt for assistance with graphics. This work was supported by grant AI020069 (P.W.K.), from the National Institutes of Health. P.W.K. holds the William H. and Rita Bell Endowed Chair in Biomedial Research.

References


Verfaillie, C.M., 1993. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood 82, 2045.


Wang, J.C.Y., Doedens, M., Dick, J.E., 1997. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89, 3919.


